Dr. Leclerc ‘s lab is interested in targeting the Receptor for Advanced Glycation End products (RAGE) in pancreatic cancer. She recently showed in a pre-clinical mouse model of pancreatic cancer, that the combination of RAGE inhibitors with gemcitabine could enhance the efficacy of gemcitabine.
Dr. Liu has been interested in developing nanomaterial-based platforms for early detection of pancreatic cancer. His group is involved in developing fast, sensitive, and cost-effective lateral-flow devices for detection of protein and micro-RNA biomarkers present in bodily fluids of pancreatic cancer patients.
Dr. Mohi Quadir is aiming to develop spatially and temporally-responsive drug delivery nano carriers for pancreatic cancer. The Quadir group is involved in designing linear and dendritic block copolymers that forms nano-sized polymersomes and vesicles capable of encapsulating frontline chemotherapeutic agents and trafficking them to specific cellular compartments without triggering off-target toxicity.
Dr. Reindl’s research is focused on the roles of small molecule phytochemicals (e.g., piperlongumin) in inducing oxidative stress which kills K-ras oncogene harboring pancreatic cancer cells. The mechanistic details, as well as therapeutic potentials of piperlongumin in combination of gemcitabine, are being investigated at both cellular and model animal levels.